Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity

Journal of Medicinal Chemistry

Volumn 48, Issue 6, 2005, Pages 1910-1918

  Heeres, Jan ^a   De Jonge, Marc R ^a   Koymans, Lucien M H ^a   Daeyaert, Frits F D ^a   Vinkers, Maarten ^a   Van Aken, Koen J A ^a   Arnold, Eddy ^b   Das, Kalyan ^b   Kilonda, Amuri ^c   Hoornaert, Georges J ^c   Compernolle, Frans ^c   Cegla, Marek ^d   Azzam, Rasha A ^e   Andries, Koen ^f   De Béthune, Marie Pierre ^g   Azijn, Hilde ^g   Pauwels, Rudi ^g   Lewi, Paul J ^a   Janssen, Paul A J ^a  

^a Center for Molecular Design   (Belgium)

^b RUTGERS UNIVERSITY   (United States)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d JAGIELLONIAN UNIVERSITY   (Poland)

^e Helwan University   (Egypt)

^f JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^g Virco BVBA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 CHLOROPHENYLAMINO) 1,6 DIMETHYL 5 (2 METHYLPHENOXY)PYRAZIN 2(1H) ONE; 3 (4 CHLOROPHENYLAMINO) 5 (2,4 DIMETHYLPHENOXY) 1,6 DIMETHYLPYRAZIN 2(1H) ONE; 3 (4 CHLOROPHENYLAMINO) 5 (2,4 DIMETHYLPHENYLTHIO) 1,6 DIMETHYLPYRAZIN 2(1H) ONE; 4 (6 MESITHYLTHIO 4 METHYL 3 OXO 3,4 DIHYDROPYRAZIN 2 YLAMINO)BENZONITRILE; 4 (6 MESITYLTHIO 4,5 DIMETHYL 3 OXO 3,4 DIHYDROPYRAZIN 2 YLAMINO)BENZONITRILE; 4 [3,4 DIMETHYL 5 OXO 6 (4 CYANOPHENYLAMINO)) 4,5 DIHYDROPYRAZIN 2 YLOXY] 3,5 DIMETHYLBENZONITRILE; 4 [4 BENZYL 3 OXO 6 (2 TOLYLOXY) 3,4 DIHYDROPYRAZIN 2 YLAMINO]BENZONITRILE; 4 [4 BENZYL 3 OXO 6 (2,4 DIMETHYLPHENOXY) 3,4 DIHYDROPYRAZIN 2 YLAMINO]BENZONITRILE; 4 [4 BENZYL 5 METHYL 3 OXO 6 (2 TOLYLTHIO) 3,4 DIHYDROPYRAZIN 2 YLAMINO]BENZONITRILE; 4 [4 METHYL 3 OXO 6 (2 TOLYLOXY) 3,4 DIHYDROPYRAZIN 2 YLAMINO]BENZONITRILE; 4 [4 METHYL 3 OXO 6 (2 TOLYLTHIO) 3,4 DIHYDROPYRAZIN 2 YLAMINO]BENZONITRILE; 4 [4,5 DIMETHYL 3 OXO 6 (2 TOLYLOXY) 3,4 DIHYDROPYRAZIN 2 YLAMINO]BENZONITRILE; 4 [4,5 DIMETHYL 3 OXO 6 (2 TOLYLTHIO) 3,4 DIHYDROPYRAZIN 2 YLAMINO]BENZONITRILE; 4 [5 METHYL 3 OXO 6 (2 TOLYLTHIO) 3,4 DIHYDROPYRAZIN 2 YLAMINO]BENZONITRILE; 4 [6 (2,4 DIMETHYLPHENOXY) 4 METHYL 3 OXO 3,4 DIHYDROPYRAZIN 2 YLAMINO]BENZONITRILE; 4 [6 (2,4 DIMETHYLPHENOXY) 4,5 DIMETHYL 3 OXO 3,4 DIHYDROPYRAZIN 2 YLAMINO]BENZONITRILE; 4 [6 (2,4 DIMETHYLPHENYLTHIO) 4 METHYL 3 OXO 3,4 DIHYDROPYRAZIN 2 YLAMINO]BENZONITRILE; 4 [6 (2,4,6 TRIMETHYLPHENOXY) 4,5 DIMETHYL 3 OXO 3,4 DIHYDROPYRAZIN 2 YLAMINO]BENZONITRILE; 4 [6 MESITYLSULFONYL 4 METHYL 3 OXO 3,4 DIHYDROPYRAZIN 2 YLAMINO]BENZONITRILE; 4 [6 MESITYLSULFONYL 4,5 DIMETHYL 3 OXO 3,4 DIHYDROPYRAZIN 2 YLAMINO]BENZONITRILE; 5 (2,4 DIMETHYLPHENOXY) 1 METHYL 3 PHENYLAMINOPYRAZIN 2(1H) ONE; 5 (2,4 DIMETHYLPHENOXY) 3 (4 CHLOROPHENYLAMINO) 1 METHYLPYRAZIN 2(1H) ONE; 5 (2,4 DIMETHYLPHENOXY) 3 (4 FLUOROPHENYLAMINO) 1 METHYLPYRAZIN 2(1H) ONE; 5 (2,4 DIMETHYLPHENOXY) 3 (4 TOLUIDINO) 1 METHYLPYRAZIN 2(1H) ONE; 5 (2,4 DIMETHYLPHENOXY)1 METHYL 3 (4 TRIFLUOROMETHYLPHENYLAMINO)PYRAZIN 2(1H) ONE; 5 MESITYLTHIO 3 (4 CHLOROPHENYLAMINO) 1 METHYLPYRAZIN 2(1H) ONE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG INHIBITION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; STRUCTURE ACTIVITY RELATION;

ANTI-HIV AGENTS; DRUG DESIGN; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; MODELS, MOLECULAR; MUTATION; PYRAZINES; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 20144374941     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040829e     Document Type: Article

References (15)

1. Smerdon, S. J.; Jäger, J.; Wang, J.; Kohlstaedt, L. A.; Chirino, A. J.; Friedman, J. M.; Rice, P. A.; Steitz, T. A. Structure of the binding site for non nucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3911-3915.
2. Arnold, E.; Das, K.; Ding, J.; Yadav, P. N. S.; Hsiou, Y.; Boyer, P. L.; Hughes, S. H. Targeting HIV reverse transcriptase for anti-AIDS drug design: Structural and biological considerations for chemotherapeutic strategies. Drug des. Discovery 1988, 13, 29-47.
3. Pauwels, R.; Andries, K.; Desmijter, J.; Schols, D.; Kukla, M. J.; Breslin, H. J.; Raeymaeckers, A.; Van Gelder, J.; Woestenborghs, R.; Heykants, J.; Schellekens, K.; Janssen, M. A. C.; De Clercq, E.; Janssen, P. A. J. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 1990, 343, 470-474.
4. Tanaka, H.; Takashima, H.; Ubasawa, M.; Sekiya, K.; Nitta, I.; Baba, M.; Shigeta, S.; Walker, R. T.; De Clercq, E.; Miyasaka, T. Synthesis and antiviral activity of 1-[(2-hydroxyethoxy)-methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents. J. Med. Chem. 1992, 35, 4713-4719.
5. Pauwels, R.; Andries, K.; Debryser, Z.; Van Daele, P.; Schols, D.; Stoffels, P.; De Vreese, K.; Woestenborghs, R.; Vandamme, A.; Janssen, C. G. M.; Anne, J.; Cauwenbergh, G.; Desmyter, J.; Heykants, J.; Janssen, M. A. C.; De Clercq, E.; Janssen, P. A. J. Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of α-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 1711-1715.
6. Goldman, M. E.; Nunberg, J. H.; O'Brien, J. A.; Quintero, J. C.; Schleif, W. A.; Freund, K. F.; Lee Gaul, S.; Saari, W. S.; Wai, J. S.; Hoffman, J. M.; Anderson, P. S.; Hupe, D. J.; Emini, E. A.; Stern, A. M. Pyridone derivatives: Specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 6863-6867.
7. Ludovici, D. W.; Kukla, M. J.; Grous, P. G.; Krishnan, S.; Andries, K.; De Béthune, M.-P.; Azijn, H.; Pauwels, R.; De Clercq, E.; Arnold, E.; Janssen, P. A. J.; Evolution of anti-HIV drug candidates. Part 1: From α-Anilinophenylacetamide (α-APA) to imidoyl thiourea (ITU). Bioorg. Med. Chem. Lett. 2001, 11, 2225-2228.
8. Ludovici, D. W.; Kavash, R. W.; Kukla, M. J.; Ho, C. Y.; Ye, H.; De Corte, B. L.; Andries, K.; De Béthune, M.-P.; Azijn, H.; Pauwels, R.; Moereels, H. E. L.; Heeres, J.; Koymans, L. M. H.; De Jonge, M. R.; Van Aken, K. J. A.; Daeyaert, F. F. D.; Lewi, P. J.; Das, K.; Arnold, E.; Janssen, P. A. J. Evolution of anti-HIV drug candidates. Part 3: Diaryltriazine (DATA) analogues. Bioorg. Med. Chem. Lett. 2001, 11, 2229-2234.
9. Ludovici, D. W.; De Corte, B. L.; Kukla, M. J.; Ye, H.; Ho, C. Y.; Lichtenstein, M. A.; Kavash, R. W.; Andries, K.; De Béthune, M.-P.; Azijn, H.; Pauwels, R.; Lewi, P. J.; Heeres, J.; Koymans, L. M. H.; De Jonge, M. R.; Van Aken, K. J. A.; Daeyaert, F. F. D.; Das, K.; Arnold, E.; Janssen, P. A. J. Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues. Bioorg. Med. Chem. Lett. 2001, 11, 2235-2239.
10. Vekemans, J.; Pollers-Wieërs, C.; Hoornaert, G. A new synthesis of substituted 2(1H)-pyrazinones. J. Heterocycl. Chem. 1983, 20, 919-923.
11. Loozen, P. K.; Tutonda, M. G.; Khorasani, M. F.; Compernolle, F.; Hoornaert, G. J. Cycloadducts of ethene with 2(1H)-pyrazinones and their conversion into 2,5-diazabicyclo[2.2.2]octane-3,6-diones. Tetrahedron 1991, 47, 9259-9268.
12. Pauwels, R.; Balzarini, J.; Baba, M.; Snoek, R.; Schols, D.; Herdewijn, P.; Desmyter, J.; De Clercq, E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 1988, 20, 309-321.
13. Das, K.; Clarc, A. D., Jr.; Lewi, P. J.; Heeres, J.; De Jonge, M. R.; Koymans, L. M. H.; Vinkers, H. M.; Daeyaert, F. F. D.; Ludovici, D. W.; Kukla, M. J.; De Corte, B. L.; Kavash, R. W.; Ho, C. Y.; Ye, H.; Lichtenstein, M. A.; Andries, K.; Pauwels, R.; De Béthune, M.-P.; Boyer, P. L.; Clark, P.; Hughes, S. H.; Janssen, P. A. J.; Arnold, E. Roles of conformational and positional adaptability in structure based design of TMC125-R165335 (Etravirine) and related nonnucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 2004, 47, 2550-2560.
14. De Jonge, M. R.; Koymans, L. M. H.; Vinkers, H. M.; Daeyaert, F. F. D.; Heeres, J.; Lewi, P. J.; Janssen, P. A. J. Structure based activity prediction of HIV-1 reverse transcriptase inhibitors. J. Med. Chem. Submitted (manuscript jm049534r).
15. Boutton, C, De Bondt, H.; De Jonge, M. R. Genotype dependent QSAR for HIV-1 protease inhibition. J. Med. Chem. Submitted (manuscript jm049596h).